Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.
A new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the virus for up to four months after patients stopped taking antiretroviral medicines.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
